LEADER 03137cam a2200301 a 4500
001 1048482
008 200930s2019 nyu b 001 0 eng
010 $a2018048368
020 $a9780062338785$q(hbk.) :$cNT$872
020 $a0062338781$q(hbk.)
035 $aNO000196284
037 $b公共圖書館臺南分區資源中心
040 $aDLC$beng$cDLC$dOCLCO$dBDX$dOCLCF$dMLY$dJNE$dKYC$dUAP$dGO3$dSLV$dZGR$dYDX$dOCLCO$dBUR$dIUK$dVP@$dDLC$dOCL$dOCLCO$dTXSCH$dNLM$dOCLCO$dGYG$dOCLCA$dLANGC$dOCLCA$dTNTNM$eaacr2
042 $apcc
043 $an-us---
050 00$aRS55.2$b.E23 2019
060 00$a2019 E-782
060 10$aQV 771
082 00$a615.1$222
090 $a臺南市立圖書館
100 1 $aEban, Katherine.
245 10$aBottle of lies :$bthe inside story of the generic drug boom /$cKatherine Eban.
250 $a1st ed.
260 $aNew York, NY :$bEcco,$cc2019.
300 $axxiv, 482 p. ;$c24 cm.
504 $aIncludes bibliographical references (p. [421]-461) and index.
505 0 $aPart I: Shifting ground. The man who saw further ; The gold rush ; A slum for the rich ; The language of quality ; Red flags -- Part II: India rises. Freedom fighters ; One dollar a day ; A clever way of doing things ; The assignment -- Part III: A cat-and-mouse business. The global cover-up ; Map of the world ; The pharaoh of pharma -- Part IV: Making a case. Out of the shadows ; "Do not give to FDA" ; "How big is the problem?" ; Diamond and ruby ; "You just don't get it" -- Part V: Detectives in the dark. Congress wakes up ; Solving for X ; A test of endurance ; A deep, dark well ; The $600 million jacket -- Part VI: The watershed. The light switch ; We are the champions ; Crashing files ; The ultimate testing laboratory -- Part VII: Reckonings. Flies too numerous to count ; Standing.
520 $a"Many have hailed the widespread use of generic drugs as one of the most important public-health developments of the twenty-first century. Today, almost 90 percent of our pharmaceutical market is comprised of generics, the majority of which are manufactured overseas. We have been reassured by our doctors, our pharmacists and our regulators that generic drugs are identical to their brand-name counterparts, just less expensive. But is this really true? Katherine Eban's Bottle of Lies exposes the deceit behind generic-drug manufacturing--and the attendant risks for global health. Drawing on exclusive accounts from whistleblowers and regulators, as well as thousands of pages of confidential FDA documents, Eban reveals an industry where fraud is rampant, companies routinely falsify data, and executives circumvent almost every principle of safe manufacturing to minimize cost and maximize profit, confident in their ability to fool inspectors. Meanwhile, patients unwittingly consume medicine with unpredictable and dangerous effects. The story of generic drugs is truly global. It connects middle America to China, India, sub-Saharan Africa and Brazil, and represents the ultimate litmus test of globalization: what are the risks of moving drug manufacturing offshore, and are they worth the savings?" -- Dust jacket.
650 0$aDrug adulteration.
650 0$aGeneric drugs$xQuality control.
650 0$aPharmaceutical industry$xCorrupt practices$zUnited States.
650 12$aDrugs, Generic$xstandards.
650 12$aFraud.
650 22$aDrug Contamination$xlegislation & jurisprudence.
650 22$aDrug Industry$xlegislation & jurisprudence.
650 22$aDrug Industry$xstandards.
650 22$aGovernment Regulation.
653 $a科技創新
653 $a知識性